Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective.

Franke, Viola; Stahlie, Emma H A; van der Hiel, Bernies; van de Wiel, Bart A; Wouters, Michel W J M; van Houdt, Winan J; van Akkooi, Alexander C J

Franke, Viola; Stahlie, Emma H A; van der Hiel, Bernies; van de Wiel, Bart A; Wouters, Michel W J M; van Houdt, Winan J; van Akkooi, Alexander C J.

Affiliation

Franke V; Departments of Surgical Oncology.
Stahlie EHA; Departments of Surgical Oncology.
van der Hiel B; Nuclear Medicine.
van de Wiel BA; Pathology at the Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Wouters MWJM; Departments of Surgical Oncology.
van Houdt WJ; Departments of Surgical Oncology.
van Akkooi ACJ; Departments of Surgical Oncology.

J Immunother ; 45(6): 263-266, 2022.

Article in En | MEDLINE | ID: mdl-35580326

Subject(s)

Herpesvirus 1, Human; Melanoma; Oncolytic Virotherapy; Skin Neoplasms; Biological Products; Chronic Disease; Humans; Immunotherapy/methods; Melanoma/drug therapy; Melanoma/pathology; Oncolytic Virotherapy/adverse effects; Oncolytic Virotherapy/methods; Skin Neoplasms/drug therapy; Skin Neoplasms/pathology; Melanoma, Cutaneous Malignant

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Herpesvirus 1, Human / Oncolytic Virotherapy / Melanoma Limits: Humans Language: En Journal: J Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google